Responses
Laboratory science
Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage
Compose a Response to This Article
Other responses
No responses have been published for this article.